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Background
Pediatric studies suggested that the actual recommended
efavirenz dosage produced insufficient plasma concentra-
tions in children. In the context of a phase II trial on once-
a-day pediatric HAART, the aims of this study were to
describe efavirenz concentration-time courses in treat-
ment naïve children, to study the effect of age and body-
weight on efavirenz pharmacokinetics and to test
relationships between doses, plasma concentrations and
efficacy.
Methods
Efavirenz concentrations were measured in 48 children
after 2 weeks of didanosine – lamivudine – efavirenz treat-
ment, and samples were available in 9/48 children
between month 2 and 5 of treatment. A total of 200 efa-
virenz plasma concentrations were collected and a popu-
lation pharmacokinetic model was developed with
NONMEM. The influence of individual characteristics was
tested using a likelihood ratio test. Estimated minimal
(Cmin), maximal (Cmax) concentrations, area under the
curve (AUC) were correlated to the decrease in HIV-1 RNA
levels after 3 months of treatment. The threshold Cmin
(and AUC) improving efficacy was determined. The target
minimal concentration of 4 mg/L was considered for tox-
icity. An optimized dosing schedule was simulated in
order that the higher percentage of children is in the effec-
tive and not toxic concentrations interval.
Results
Efavirenz pharmacokinetics was best described by a one-
compartment model with first order absorption and elim-
ination. Mean efavirenz apparent elimination clearance
and volume of distribution were respectively 0.211 L/h/kg
and 4.48 L/kg. The elimination clearance significantly
decreased with age. With the recommended doses given to
46 out of the 48 children, 19 % had a minimal concentra-
tion below 1 mg/L; they were 44 % under this limit in the
less than 15 kg children. A significant higher percentage of
children with Cmin > 1.1 mg/L (or AUC > 51 mg/L.h) had
a viral load decrease greater than 2 log10 copies/mL after 3
months of treatment, compared to children below these
values.
Conclusion
To optimize the percentage of children with a Cmin
between 1.1 and 4 mg/L, children should receive the fol-
lowing once daily efavirenz dose: 25 mg/kg from 2 to 6
years, 15 mg/kg from 6 to 10 years and 10 mg/kg from 10
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to 15 years. These assumptions should be prospectively
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